OncoMatch/Colorectal Cancer (CRC)/MLH1
Colorectal Cancer (CRC)MLH1 Clinical Trials
MLH1 promoter hypermethylation — the most common cause of sporadic dMMR CRC — silences MLH1 expression in approximately 10–15% of colorectal cancers and confers MSI-H status. MLH1/PMS2 co-loss is the typical IHC pattern for sporadic dMMR, predicting response to checkpoint immunotherapy. Pembrolizumab monotherapy is the first-line standard of care for MLH1-deficient/dMMR metastatic CRC.
Top recruiting MLH1 Colorectal Cancer (CRC) trials
Ranked by phase and US site count.
See all trials matched to your profile →Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients
Sun Yat-sen University
PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer
Sun Yat-sen University
Node-Sparing Short-Course Radiotherapy Sequential Chemotherapy and PD-1 Inhibitor for Mid/Low pMMR/MSS Rectal Cancer (MODIFI-RC-II)
Sixth Affiliated Hospital, Sun Yat-sen University
Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer
National Cancer Institute, Naples
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Marengo Therapeutics, Inc.
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
Memorial Sloan Kettering Cancer Center
More MLH1 Colorectal Cancer (CRC) trials
14 international trials (no US sites)
Browse other molecular targets with active Colorectal Cancer (CRC) trials.